Wandercraft is carrying exoskeleton proof into humanoid factory work

Wandercraft announced $75 million in equity and debt on June 11, 2025 with a real clinical base under its humanoid factory story. The company says Atalante X is used in more than 100 rehabilitation centers across four continents, and that 2,500 people with mobility disabilities have taken more than 14 million steps with its systems.

The funding covers Eve, Atalante X, and Calvin-40 without forcing them into one market. Wandercraft plans to move Eve toward personal exoskeleton commercialization, expand Atalante X clinical adoption, and develop Calvin-40 for industrial work. Rehabilitation proof becomes the bridge into home mobility and factory tasks.

Renault gives Calvin-40 a sharper industrial signal than a standalone reveal. Wandercraft said Renault Group took a minority stake and became the first commercial partner and customer for Calvin-40, bringing manufacturing expertise to help scale production. Calvin-40 was developed in 40 days using Wandercraft's robotics platform with NVIDIA Isaac technologies, including Isaac GR00T N1 and Jetson edge AI.

Wandercraft was founded in 2012 in France by Nicolas Simon, Alexandre Boulanger, Matthieu Masselin, and Jean-Louis Constanza after early bipedal-robotics work at Ecole Polytechnique. Its platform uses a proprietary neural network trained on billions of steps and refined through clinical use. That locomotion base gives Calvin-40 a different origin from humanoids that begin with warehouse manipulation or teleoperation data.

The competitive field splits across two markets. In rehabilitation, Wandercraft sits near Ekso Bionics, ReWalk, Cyberdyne, and other exoskeleton systems. In industrial humanoids, Calvin-40 is closer to Figure, Apptronik, Agility Robotics, Tesla Optimus, and Renault's own automation options. Wandercraft's distinction is clinical locomotion proof: self-balancing walking technology tested through rehabilitation use before being pointed at factory work.

The proof boundary is transfer. Atalante X has clinical adoption and regulatory context, while Calvin-40 has Renault customer context but not factory payload cycles, task completion rates, uptime, or production economics. Wandercraft's strategic bet is that clinical-grade balance and walking control can become industrial mobility infrastructure, carrying exoskeleton discipline into humanoid factory work without losing reliability at the handoff.

Have a robotics update Korthos should review? Send news, deployments, product releases, funding rounds, research, or media to tips@korthos.xyz or reach out on X at @agkorthos.